Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases

MLA

Manja, Friese-Hamim, et al. “Brain Penetration and Efficacy of Tepotinib in Orthotopic Patient-Derived Xenograft Models of MET-Driven Non-Small Cell Lung Cancer Brain Metastases.” Lung Cancer, vol. 163, Jan. 2022, pp. 77–86. EBSCOhost, https://doi.org/10.1016/j.lungcan.2021.11.020.

APA

Manja, F.-H., Anderson, C., Dominique, P., Lindsey, C., Christof, R., Olga, B., Hong, Z., Timothy, C., Jing, L., Jianguo, M., David, B., Jürgen, S., Martin, S., & Christopher, S. (2022). Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases. Lung Cancer, 163, 77–86. https://doi.org/10.1016/j.lungcan.2021.11.020

Chicago

Manja, Friese-Hamim, Clark Anderson, Perrin Dominique, Crowley Lindsey, Reusch Christof, Bogatyrova Olga, Zhang Hong, et al. 2022. “Brain Penetration and Efficacy of Tepotinib in Orthotopic Patient-Derived Xenograft Models of MET-Driven Non-Small Cell Lung Cancer Brain Metastases.” Lung Cancer 163 (January): 77–86. doi:10.1016/j.lungcan.2021.11.020.